HKSE · 1177.HK
Sino Biopharmaceutical Limited
HK$4.85-HK$0.01 (-0.1%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.23% below the high.
Loading market information…
HKSE · 0460.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:51 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sihuan Pharmaceutical Holdings Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sihuan Pharmaceutical Holdings Group Ltd.’s forward annual dividend is HK$0.01 per share, paid annual. The forward yield is 1.49% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sihuan Pharmaceutical Holdings Group Ltd.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sihuan Pharmaceutical Holdings Group Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2022 |
|---|
| Mar 24, 2023 |
| -HK$0.24 |
| HK$816.59M-73.05% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$4.85-HK$0.01 (-0.1%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.23% below the high.
HK$4.62+HK$0.13 (+2.78%)
China Resources Pharmaceutical Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.25% below the high.
HK$9.93+HK$0.02 (+0.15%)
China Medical System Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.05% below the high.
HK$4.37+HK$0.05 (+1.04%)
Grand Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.84% below the high.
HK$6.84-HK$0.02 (-0.22%)
The United Laboratories International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
HK$140.20-HK$0.80 (-0.57%)
Fujian Haixi Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.64% below the high.
HK$2.60+HK$0.02 (+0.78%)
SSY Group Limited’s quoted price sits in the upper half of its reported 52-week range, 18.24% below the high.
HK$1.60+HK$0.03 (+1.59%)
Luye Pharma Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 51.22% below the high.
